Can Mounjaro Cause DVT? Making Sense of the Evidence

Why people ask whether Mounjaro could trigger a blood clot

A question our prescribers hear most weeks is whether starting Mounjaro could increase the chance of developing a clot in the leg or lung. It is a fair concern. GLP-1 and dual-agonist medicines are relatively new, awareness of side effects is growing, and symptoms of DVT (leg swelling, warmth, redness) can overlap with the muscle aches some people notice in the first weeks of treatment. The worry is understandable, and it deserves a straight answer rather than a brush-off.

The honest position is that DVT is not a recognised adverse reaction for tirzepatide. Reviewing the NHS tirzepatide medicines page and the licensed product information, venous thromboembolism does not appear in the side-effect listings at any frequency tier — common, uncommon or rare. The SURMOUNT-1 trial, which ran for 72 weeks across nearly 2,600 adults with obesity, did not flag clotting events as a drug-related finding. That is meaningful evidence, though it is not a guarantee, and if you have specific risk factors the conversation belongs with a prescriber, not a search engine.

If you want a broader picture of what Mounjaro has and has not been associated with, the full overview of reported Mounjaro effects covers the current evidence across all body systems.

The obesity-DVT connection, and why it complicates the picture

Separating a medicine's effects from the condition it treats is harder than it sounds. Obesity raises the risk of DVT through several routes: increased pressure on deep leg veins, altered coagulation factors, reduced physical activity, and chronic low-grade inflammation. This means that a person starting Mounjaro for weight management already carries a higher baseline clotting risk than the general population, not because of the medicine, but because of the condition being treated.

Clinical trials account for this by comparing rates in treated versus control groups rather than measuring absolute numbers. In the SURMOUNT programme, no excess clotting signal emerged in the tirzepatide arms relative to placebo. Losing significant body weight over time is actually expected to reduce DVT risk, since adipose tissue and venous pressure both fall. The NICE appraisal of tirzepatide (TA1026) considered the overall safety profile favourably, which would not have been the case had a clotting signal been detected.

If you are considering tirzepatide specifically and want to understand the full licensed indication and mechanism, the tirzepatide overview sets out the detail.

Factors your prescriber will weigh when DVT history is part of your picture

The prescription-only status of Mounjaro exists for exactly this kind of nuanced assessment. A personal or family history of DVT, active thrombophilia, recent surgery, immobility, or concurrent use of oral contraceptives are all factors that shift the calculus. None of them automatically rules out treatment, but each one changes the conversation.

Dehydration is worth raising separately. The GI side effects common in the early weeks of tirzepatide (nausea, reduced appetite, occasional vomiting) can lead to reduced fluid intake, which affects blood viscosity. This is not a mechanism for DVT specific to tirzepatide; it applies to any illness or medicine that reduces oral hydration. Staying well-hydrated and knowing the signs of dehydration are standard advice at the start of treatment. If you are also on oral contraception, note that tirzepatide can affect pill absorption in the first four weeks and after each dose increase, so a non-oral method should be added during those windows, something to discuss with your prescriber alongside any clotting history.

For people researching how tirzepatide compares on other safety questions, the dedicated tirzepatide and DVT page goes into the pharmacology in more detail. And for a broader look at how Mounjaro's safety profile is described across all available evidence, the Mounjaro and DVT reference page is the right next stop.

When to seek medical advice, and what to do if you are concerned

No educational page replaces a clinical assessment. If you are already on Mounjaro and develop new leg swelling, pain in one calf, chest pain, breathlessness, or coughing up blood, seek urgent medical attention. These could indicate DVT or pulmonary embolism and need assessment that day, do not wait for a routine appointment.

If your concern is more prospective (you are thinking about starting treatment and want to know whether your history makes DVT a relevant consideration) the right place to raise it is your consultation. Separate questions also come up regularly around other body systems, including whether Mounjaro can cause IBS and, for those who have seen it mentioned online, whether Mounjaro could be linked to MS, both of which our prescribers are asked about. At nume, a real prescriber reads every submission the same day, and clotting history is exactly the kind of detail that shapes whether, when and how treatment is recommended. You can also report any unexpected symptom you suspect may be related to your medicine at the MHRA Yellow Card scheme, which helps regulators track any safety signals that emerge after a medicine is licensed.

Thinking about whether treatment is right for your situation? Check your eligibility with our prescribers, the consultation is free, and there is no obligation to proceed.